CSIMarket


Respirerx Pharmaceuticals Inc   (RSPI)
Other Ticker:  
 


 

Respirerx Pharmaceuticals Inc

RSPI's Financial Statements and Analysis



Respirerx Pharmaceuticals Inc narrowed second quarter of 2023 net loss per share of $0.00 compare to net loss per share of $-0.01 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.01 realized in previous quarter.


second quarter of 2023
Earnings Per Share Revenues
$ 0 $  0 Mill
$+0.01     Unch.    



Respirerx Pharmaceuticals Inc 's Revenue fell by 0 % in second quarter of 2023 (Jun 30 2023) year on year, to $0 million and declined by sequentially.


Respirerx Pharmaceuticals Inc is Expected to report next financial results on April 16, 2024.

More on RSPI's Income Statement



Respirerx Pharmaceuticals Inc 's in thesecond quarter of 2023 recorded net loss of $-0.692 million, an improvement compare to net loss of $-0.832 million in II. Quarter a year ago.

Sequentially net loss advanced

More on RSPI's Growth

Respirerx Pharmaceuticals Inc Inventories
RSPI's Cash flow In the second quarter of 2023 company's net cash flow was $0 million


Respirerx Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Respirerx Pharmaceuticals Inc payed $ 0.00 cash per share, on a free-cash flow basis .


Tangible Book value grew to $ -0.07 per share from $ -0.09.

Company issued 31.03 million shares or 22.62 % in Jun 30 2023.


More on RSPI's Dividends

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 168
 Total Debt (Millions $) 1
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Respirerx Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Respirerx Pharmaceuticals Inc had negative $ 0.00 cash flow per share, on a free-cash flow basis .


Tangible Book value grew to $ -0.07 per share from $ -0.09.

Company issued 31.03 million shares or 22.62 % in Jun 30 2023.


More on RSPI's Balance Sheets

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 168
 Total Debt (Millions $) 1
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Respirerx Pharmaceuticals Inc Earnings

Respirerx Pharmaceuticals Inc defies expectations with brilliant policy implementation, emerging as major player in Pharmaceutical Preparations industry

The stock market is buzzing with exciting updates as the April to June 30, 2023 reporting season unfolds. Many entities have already announced their earnings, including several major players in the thriving Major Pharmaceutical Preparations industry. Among these entities is Respirerx Pharmaceuticals Inc (RSPI), which recently reported an operating shortfall of $-0.465859 million for the financial interval ending June 30, 2023.
Analyzing the financial performance of a company during a specific period provides valuable insights into its growth and potential. It paints a picture of how well an organization has fared within a given timeframe and allows investors to make informed decisions. The second quarter...

Dramatic Upward Surge in Q1 2023 Favors Shareholders, as Major Pharma Outfit, Respirerx Pharmaceuticals Inc, Reveals Operating Deficit of Just $-0.390374 Million!

The Major Pharmaceutical Preparations sector is in trouble, and this has been reinforced by the recent analysis of the first quarter of 2023 numbers. The veteran experts from the industry have observed an operating deficit of a significant $-0.390374 million, which is a worrying sign. What is even more concerning is that there is still no sight of any revenue being mentioned in the financial reporting period from January to March 31, 2023. This indicates that the sector is struggling to generate any income, and this could spell disaster for the companies operating in this space.
The performance of the first quarter of 2022 is a perfect indication of the declining health of the industry. At that time, the...


Date modified: 2023-08-25T21:47:42+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com